FDA drug approvals : time Is money!
Andreas Sturm, Michael J. Dowling and Klaus Röder
We investigated the stock price behavior of public pharmaceutical and biotechnology companies upon approval of a drug by the Food and Drug Administration (FDA). Using event study methodology, we examine the reaction caused by the approval, separating it from the asset price movements caused by other factors such as market and industry effects. The results are then used to validate the model developed in this article as an alternative to the explanations given by Sharma and Lacey (2004). The results of this study support the Efficient Market Hypothesis, i.e. that the market reacts to the new information quickly and clearly.
Year of publication: |
2007
|
---|---|
Authors: | Sturm, Andreas ; Dowling, Michael J. ; Röder, Klaus |
Published in: |
Journal of entrepreneurial finance : JEF ; official publication of The Academy of Entrepreneurial Finance. - Montrose, Calif, ISSN 1551-9570, ZDB-ID 26141723. - Vol. 12.2007, 2, p. 23-53
|
Saved in:
freely available
Saved in favorites
Similar items by person
-
FDA drug approvals: Time Is money!
Sturm, Andreas, (2007)
-
FDA drug approvals : time Is money!
Sturm, Andreas, (2007)
-
FDA Drug Approvals: Time Is Money!
Sturm, Andreas, (2007)
- More ...